Executive Interviews
EXECUTIVE INTERVIEW - Resilience: From Complexity to Clarity - Sharpening Focus for Long-Term Performance in a More Demanding CDMO Era
Catherine Hanley, VP, Head of Marketing and Corporate Communications, explains how the company has rebalanced its network and aligned around its core strengths in biologics and sterile fill/finish manufacturing.
EXECUTIVE INTERVIEW - Vetter Pharma: Why Fill-Finish Matters More Than Ever – & the Trends Behind It
Carsten Press, one of Vetter’s Managing Directors, discusses the key trends shaping CDMO innovation in today’s dynamic market – and how the family-owned company is integrating these trends into its forward-looking strategy to support consistent quality and seamless drug delivery.
EXECUTIVE INVTERVIEW - Klotho Neurosciences: Focused on Neurodegenerative & Age-Related Disorders
Dr. Joseph Sinkule, Founder & CEO of Klotho Neurosciences, discusses the company, its therapies, the human Klotho gene, and longevity.
EXECUTIVE INTERVIEW - Lonza: Addressing Solubility Challenges in Early Stages of Drug Development
Adi Kaushal, Director and Technology Head, Bioavailability Enhancement, at Lonza, discusses solubility issues and Lonza’s approach to addressing these challenges in the early stages of drug development.
EXECUTIVE INTERVIEW - Incannex Healthcare: Pioneering the Future of Cannabinoid & Psychedelic Therapies
Joel Latham, CEO of Incannex Healthcare, shares how the company navigates complex global regulatory pathways, building strategic collaborations, and forging a path toward commercial success.
EXECUTIVE INTERVIEW - CERo Therapeutics: A Novel Approach to Treating Cancer
Chris Ehrlich, CEO of CERo Therapeutics, discusses the company’s science, clinical program, the treatment landscape, and more.
EXECUTIVE INTERVIEW - Plus Therapeutics: Advancing Targeted Radiotherapeutics for Rare & Difficult-to-Treat Cancers
Dr. Marc Hedrick, CEO of Plus Therapeutics, discusses the company’s targeted radiotherapeutic platform for central nervous system and solid tumor cancers and why internal radiation therapy offers patients a more advanced drug delivery solution compared to traditional external radiation therapy.
EXECUTIVE INTERVIEW - Intensity Therapeutics: Providing Cancer Patients With Treatments That Work
Lew Bender, Founder and CEO of Intensity Therapeutics, discusses the company’s science, clinical program, the drug development process, and more.
EXECUTIVE INTERVIEW - Lonza & Ethris: Advancing mRNA Vaccines: Room-Temperature Stable, Spray-Dried Formulations for Enhanced Mucosal Delivery
Kim Shepard, Director of Advanced Drug Delivery at Lonza, and Carsten Rudolph, PhD, Co-founder and Chief Executive Officer at Ethris, discuss the main objectives of the collaboration and the benefits of spray-dried mRNA vaccines.
EXECUTIVE INTERVIEW - ALZpath: A Diagnostic Assay Changing the Future of Alzheimer’s Disease
Jacob Hunter, Chief Business Officer, ALZpath, Inc., discusses the development and deployment of the company’s proprietary pTau217 antibody, bridging the gap between detection and treatment to improve patient outcomes globally.
EXECUTIVE INTERVIEW - Adare Pharma Solutions: Fast, Flexible, and Focused: The Secrets of a Successful CDMO Partnership
Steven Facer, Senior Vice President of Sales and Marketing at Adare Pharma Solutions, shares practical insights on what makes CDMO partnerships work and what can cause them to fall short.
EXECUTIVE INTERVIEW - Sanner Group: Building a Suite of World-Leading Services for its Customers
Chris Gilmor, Vice President of Sales, Sanner of America, explains how Sanner’s Advance with Agility™ program helps its partners achieve faster development times and reduce time to market, and how the company embeds sustainable practices into its global business.
EXECUTIVE INTERVIEW - PCI Pharma Services: Driving Precision, Agility & Partnership in Complex Drug Development
Anshul Gupte, PhD, RAC Drugs, VP of Pharmaceutical Development at PCI Pharma Services, talks about phase-appropriate development, technical hurdles in pharmaceutical sciences, building agile teams, and what sponsors should prioritize when planning their strategy for novel therapies.
EXECUTIVE INTERVIEW - Botanical Solution Inc.: Launching a Revolution in Economical & Environmentally Sustainable QS-21 Vaccine Adjuvant Production
Gastón Salinas, CEO of Botanical Solution Inc., discusses his company’s transition from agriculture to pharmaceuticals, addressing the global shortage of QS-21, and developing the QS-21 gold standard vaccine.
EXECUTIVE INTERVIEW - Salipro Biotech & Bio-Rad Laboratories: A Powerful Solution for Antibody Discovery Against Challenging Transmembrane Targets
Dr. Jens Frauenfeld, CEO, Salipro Biotech, and Dr. Francisco Ylera, R&D Team Lead at Bio-Rad Laboratories, explain how their collaboration is leveraging the Salipro® platform alongside Bio-Rad’s Pioneer™ Antibody Discovery Platform to target transmembrane proteins.
EXECUTIVE INTERVIEW - Gelteq: A Breakthrough Ingestible Gel Drug & Nutrient Delivery System
Nathan Givoni, Co-Founder and CEO of Gelteq, discusses challenges with traditional drug delivery and the company’s innovative ingestible gel platform designed for drug and nutrient delivery.
EXECUTIVE INTERVIEW - MediWound Ltd.: Developing a New Class of Biologic Enzymatic Therapeutic Products to Debride Wounds
Ofer Gonen, Chief Executive Officer of MediWound, discusses the company’s innovative approach to debridement.
EXECUTIVE INTERVIEW - Lonza: Driving Innovation & Sustainability: CDMO Trends & the Future of ADCs
Sebastian Stenderup, Executive Director, Head of Commercial EMEA, Lonza, discusses some of the trends CDMOs are currently facing, from the growth of ADCs to the importance of sustainability, and how his company is responding to them.
EXECUTIVE INTERVIEW - How Vetter’s Expansion of its Senior Management Team Aligns With Prioritization of Strategic Growth
Vetter’s leadership discusses the company’s vision for strategic restructuring, their insights on Contract Development and Manufacturing trends in 2025, and what this strategic change means for the sustainable growth of the company and its global expansion.
EXECUTIVE INTERVIEW - Resilience Rising: Advancing Therapies That Transform Lives
Dr. Susan Billings, Chief Commercial Officer of Resilience, discusses pressing issues in the CDMO space, the opportunities driving innovation, and how her company is shaping the future of drug substance and drug product manufacturing.
